CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Income from Continuing Operations came in at 3115000.0 in Q1 2026, down 89.02% YoY from 28361988.95 in Q1 2025, and up 90.26% on a QoQ basis from 31983000.0 in Q4 2025.
CollPlant Biotechnologies (CLGN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Income from Continuing Operations data on file, last reported at 3115000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 89.02% year-over-year to 3115000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35427000.0 (down 421.98% YoY) and the FY2025 annual result came in at 39936000.0, down 1.67% from the prior year.
- Income from Continuing Operations climbed to 3115000.0 in Q1 2026, from 31983000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5504000.0 in Q2 2023 to a low of 31983000.0 in Q4 2025.
- A 5-year average of 4178470.59 and a median of 3507000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 231.52% — and 2025, when it sank 578.47%.
- Tracing CLGN's Income from Continuing Operations over 5 years: stood at 27142000.0 in 2022, then soared by 81.49% to 5023000.0 in 2023, then grew by 6.15% to 4714000.0 in 2024, then slumped by 578.47% to 31983000.0 in 2025, then surged by 90.26% to 3115000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3115000.0 (Q1 2026), 31983000.0 (Q4 2025), and 3507000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | -3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | -3.12 Mn |
| Dec 31, 2025 | -31.98 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 30, 2025 | -1.65 Mn |
| Dec 31, 2024 | -4.71 Mn |
| Sep 30, 2024 | -4.50 Mn |
| Jun 30, 2024 | 4.07 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Dec 31, 2023 | -5.02 Mn |
| Sep 30, 2023 | -4.72 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Mar 31, 2023 | 3.24 Mn |
| Dec 31, 2022 | -27.14 Mn |
| Sep 30, 2022 | -4.47 Mn |
| Jun 30, 2022 | -4.19 Mn |
| Mar 31, 2022 | 3.77 Mn |
| Dec 31, 2021 | -228.29 Mn |
| Sep 30, 2021 | 71.91 Mn |
| Jun 30, 2021 | -2.98 Mn |